, Volume 72, Issue 17, pp 2187–2205 | Cite as

Advances in Drug Development for Acute Migraine

Leading Article


Triptans revolutionized medical recognition and the acute treatment of migraine. Yet, throughout a lifetime, millions of patients who live with migraine endure hundreds of days of disability due to their disease. Most migraine attacks respond to migraine-specific interventions, but attack response does not predict patient response. Generally, migraine patients respond to acute treatment for some, but not necessarily all, attacks of migraine. Consequently, there remains a substantial unmet clinical need for better acute treatment of migraine.

Numerous avenues of research and clinical observation provide insight into potential advances in acute treatment of migraine. These include better delivery systems for existing drugs, as well as the development of potential new therapeutic agents. In addition, new changes in migraine taxonomy and clinical observations of migraine suggest additional important therapeutic opportunities. Based on clinical observations, this article explores future acute treatment needs, drugs in development for acute migraine, and new products that deliver established drugs to improve treatment response.



The authors received no external funding or support for the preparation of this manuscript. The authors wish to acknowledge the contributions of Jessica Hall for assistance with writing the manuscript.

Dr Roger Cady currently serves on several advisory boards: Allergan, Astellas, MAP Pharmaceuticals, Merck & Co, Inc., Novartis, Ortho-McNeil Neurologics and Zogenix. He also receives research grants from Allergan, Boston Scientific, Bristol Myers, GlaxoSmithKline, Merck & Co., Inc., Opti Nose, Pura Med Bioscience and Zogenix. Dr Cady has provided consulting services for Allergan, Astellas, GlaxoSmithKline, Merck & Co., Inc. and Ortho-McNeil Neurologics.

Candace Shade has no conflicts of interest that are directly relevant to the content of this article. Ryan Cady has no conflicts of interest that are directly relevant to the content of this article.


  1. 1.
    Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009 May; 27(2): 321–34PubMedCrossRefGoogle Scholar
  2. 2.
    Stewart WF, Wood C, Reed ML, et al., AMPP Advisory Group. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008 Nov; 28(11): 1170–8PubMedCrossRefGoogle Scholar
  3. 3.
    Chugani DC, Niimura K, Chaturvedi S, et al. Increased brain serotonin synthesis in migraine. Neurology 1999 Oct 22; 53(7): 1473–9PubMedCrossRefGoogle Scholar
  4. 4.
    Ayata C. Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 2009 Oct; 29(10): 1095–114PubMedCrossRefGoogle Scholar
  5. 5.
    Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005 Nov; 58(5): 698–705PubMedCrossRefGoogle Scholar
  6. 6.
    Wolff HG. Headache in the migraine syndrome: headache and other head pain. 2nd ed. New York: Oxford University Press, 1963: 227–385Google Scholar
  7. 7.
    Olesen J, Friberg L, Skyhoj-Olsen T, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28: 791–8PubMedCrossRefGoogle Scholar
  8. 8.
    Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967 May; 16(5): 544–52PubMedCrossRefGoogle Scholar
  9. 9.
    Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl. 9: 23–33PubMedGoogle Scholar
  10. 10.
    Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989 May; 10(5): 200–4PubMedCrossRefGoogle Scholar
  11. 11.
    Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache. CNS Drugs 2001; 15(10): 745–53PubMedCrossRefGoogle Scholar
  12. 12.
    Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831–5PubMedCrossRefGoogle Scholar
  13. 13.
    No authors listed. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991 Aug 1; 325(5): 316–21Google Scholar
  14. 14.
    Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000 Dec; 60(6): 1259–87PubMedCrossRefGoogle Scholar
  15. 15.
    Belvís R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov 2009 Jan; 4(1): 70–81PubMedCrossRefGoogle Scholar
  16. 16.
    Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia 2011 Jul; 31(9): 1015–22PubMedCrossRefGoogle Scholar
  17. 17.
    Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668–75PubMedCrossRefGoogle Scholar
  18. 18.
    Hu XH, Ng-Mak D, Cady R. Does early migraine treatment shorten time to headache peak and reduce its severity? Headache 2008; 48: 914–20PubMedCrossRefGoogle Scholar
  19. 19.
    Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analysis of data from three clinical trials. Clin Ther 2000; 22: 1035–48PubMedCrossRefGoogle Scholar
  20. 20.
    Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000; 40: 792–7PubMedCrossRefGoogle Scholar
  21. 21.
    Goadsby PJ. The ‘Act when Mild’ (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalagia 2008; 28 Suppl. 2: 36–41CrossRefGoogle Scholar
  22. 22.
    Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 2007 Sep; 27(9): 1055–60PubMedCrossRefGoogle Scholar
  23. 23.
    Mathew NT, Finlayson G, Smith TR, et al., AEGIS Investigator Study Group. Early intervention with almotriptan: results of the AEGIS trial (AXERT early migraine intervention study). Headache 2007 Feb; 47(2): 189–98PubMedCrossRefGoogle Scholar
  24. 24.
    Dodick DW. Applying the benefits of the AwM study in the clinic. Cephalalgia 2008; 28 Suppl. 2: 42–9PubMedCrossRefGoogle Scholar
  25. 25.
    Foley KA, Cady RK, Martin V, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538–54PubMedCrossRefGoogle Scholar
  26. 26.
  27. 27.
    Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol 2011 Feb; 13(1): 1–14PubMedCrossRefGoogle Scholar
  28. 28.
    Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1–96Google Scholar
  29. 29.
    Blau JN. Adult migraine: the patient observed. In: Blau JN, editor. Migraine: clinical and research aspects. Baltimore (MD): Johns Hopkins University Press, 1987: 3–17Google Scholar
  30. 30.
    Raskin NH, Appenzellar O. Headache. In: Major problems in internal medicine. Vol. 19. Philadelphia (PA): W.B. Saunders, 1980Google Scholar
  31. 31.
    Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982; 22: 66–8PubMedCrossRefGoogle Scholar
  32. 32.
    Bedell AW, Cady RK, Diamond ML, et al. Patient-centered strategies for effective management of migraine. Springfield (MO): Primary Care Network, 2000Google Scholar
  33. 33.
    Cady R, Schreiber C, Farmer K, et al. Primary headaches: a convergence hypothesis. Headache 2002; 42: 204–16PubMedCrossRefGoogle Scholar
  34. 34.
    Cady RK, Schreiber CP, Farmer KU. Understanding the patient with migraine: the evolution from episodic headache to chronic neurological disease. Headache 2004; 44: 426–35PubMedCrossRefGoogle Scholar
  35. 35.
    Headache Classification Committee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 Suppl. 1: 1–160Google Scholar
  36. 36.
    Bigal ME, Rapoport AM, Sheftell FD, et al. The International Classification of Headache Disorders revised criteria for chronic migraine: field testing in a headache specialty clinic. Cephalalgia 2007 Mar; 27(3): 230–4PubMedCrossRefGoogle Scholar
  37. 37.
    Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26(6): 742–6PubMedCrossRefGoogle Scholar
  38. 38.
    Lipton RB, Chu MK. Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Rev Neurother 2009; 9: 1451–4PubMedCrossRefGoogle Scholar
  39. 39.
    Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71: 559–66PubMedCrossRefGoogle Scholar
  40. 40.
    Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48: 1157–68PubMedCrossRefGoogle Scholar
  41. 41.
    Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002 Oct 8; 59(7): 1011–4PubMedCrossRefGoogle Scholar
  42. 42.
    Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache center: clinical characteristics and treatment outcomes. Cephalalgia 2004; 24: 483–90PubMedCrossRefGoogle Scholar
  43. 43.
    Silberstein SD, Olesen J, Bousser M-G, et al. The International Classification of Headache Disorders, 2nd edition (ICHD-II): revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005; 25(6): 460–5PubMedCrossRefGoogle Scholar
  44. 44.
    Lyseng-Williamson KA, Frampton JE. Onabotulinumtox-in A (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine. CNS Drugs 2012 Aug 1; 26(8): 717–23PubMedCrossRefGoogle Scholar
  45. 45.
    Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010 Apr; 81(4): 428–32PubMedCrossRefGoogle Scholar
  46. 46.
    Cady R, Farmer K, Dexter JK, et al. Cosensitization of pain and psychiatric comorbidity in chronic daily headache. Curr Pain Headache Rep 2005 Feb; 9(1): 47–52PubMedCrossRefGoogle Scholar
  47. 47.
    Waberzinek G, Marková J, Mastík J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett 2007 Feb; 28(1): 59–64PubMedGoogle Scholar
  48. 48.
    Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998 Jul; 51(1): 307–9PubMedCrossRefGoogle Scholar
  49. 49.
    Lindegaard KF, Övrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks: a double-blind placebo-controlled cross-over study. Headache 1980; 20(2): 96–8PubMedCrossRefGoogle Scholar
  50. 50.
    Neuman M, Demarez JP, Harmey JL, et al. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharmacol Res 1986; 6(1): 11–3PubMedGoogle Scholar
  51. 51.
    Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology 1991 Jun; 41(6): 786–93PubMedCrossRefGoogle Scholar
  52. 52.
    Allais G, Bussone G, De Lorenzo C, et al. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations. Neurol Sci 2007; 28 Suppl. 2: S225–8PubMedCrossRefGoogle Scholar
  53. 53.
    Luciani R, Carter D, Mannix L, et al. Prevention of migraine during prodrome with naratriptan. Cephalalgia 2000 Mar; 20(2): 122–6PubMedCrossRefGoogle Scholar
  54. 54.
    Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009 Nov; 29(11): 1133–48PubMedCrossRefGoogle Scholar
  55. 55.
    Lipton RB, Stewart WF, Cady R, et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000; 40: 783–91PubMedCrossRefGoogle Scholar
  56. 56.
    Chakravarty A. How triggers trigger acute migraine attacks: a hypothesis. Med Hypotheses 2010 Apr; 74(4): 750–3PubMedCrossRefGoogle Scholar
  57. 57.
    Aurora SK, Wilkinson F. The brain is hyperexcitable in migraine. Cephalalgia 2007; 27(12): 1442–53PubMedCrossRefGoogle Scholar
  58. 58.
    Lipton RB. Epilepsy and migraine as comorbid disorders: epidemiologic perspectives. Adv Stud Med 2005; 5(6E): S649–57Google Scholar
  59. 59.
    Weir GA, Cader MZ. New directions in migraine. BMC Med 2011 Oct 25; 9: 116PubMedCrossRefGoogle Scholar
  60. 60.
    Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005; 366: 371–7PubMedCrossRefGoogle Scholar
  61. 61.
    De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33: 192–6PubMedCrossRefGoogle Scholar
  62. 62.
    Hansen JM, Thomsen LL, Olesen J, et al. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia 2008 May; 28(5): 496–505PubMedCrossRefGoogle Scholar
  63. 63.
    Lance JW. Current concepts of migraine pathogenesis. Neurology 1993 Jun; 43 (6 Suppl 3): S11–5PubMedGoogle Scholar
  64. 64.
    Buzzi MG, Cologno D, Formisano R, et al. Prodromes and the early phase of the migraine attack: therapeutic relevance. Funct Neurol 2005 Oct–Dec; 20(4): 179–83PubMedGoogle Scholar
  65. 65.
    Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136–42PubMedCrossRefGoogle Scholar
  66. 66.
    Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001; 53: 167–78PubMedCrossRefGoogle Scholar
  67. 67.
    Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 2003 Aug; 126 Pt 8: 1801–13PubMedCrossRefGoogle Scholar
  68. 68.
    Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol 2012 Jun; 8(2): 89–99PubMedCrossRefGoogle Scholar
  69. 69.
    Cady RK, Voirin J, Farmer K, et al. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications. Headache 2012 May; 52(5): 749–64PubMedCrossRefGoogle Scholar
  70. 70.
    Diener HC, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2010; 31(5): 573–84PubMedCrossRefGoogle Scholar
  71. 71.
    Pfaffenrath V, Fenzl E, Bregman D, et al. Intranasal ketorolac tromethamine (SPRIX®) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia 2012 Jul; 32(10): 766–77PubMedCrossRefGoogle Scholar
  72. 72.
    Färkkilä M, Diener HC, Géraud G, et al., COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012 May; 11(5): 405–13PubMedCrossRefGoogle Scholar
  73. 73.
    Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 2011 Apr; 51(4): 507–17PubMedCrossRefGoogle Scholar
  74. 74.
    Cady RK, Goldstein J, Nett R, et al. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Headache 2011 Jul–Aug; 51(7): 1078–86Google Scholar
  75. 75.
    Djupesland PG, Docekal P, Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by novel breath-actuated bi-directional device for the acute treatment of migraine: a randomized placebo-controlled study. Cephalalgia 2010 Aug; 30(8): 933–42PubMedGoogle Scholar
  76. 76.
    Kahn K. Cambia® (diclofenac potassium for oral solution) in the management of acute migraine. US Neurology 2011; 7(2): 139–43Google Scholar
  77. 77.
    Cady RK, Aurora SK, Brandes JL, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 2011 Sep; 51(8): 1202–11PubMedCrossRefGoogle Scholar
  78. 78.
    Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004 Jul; 24(7): 596–602PubMedCrossRefGoogle Scholar
  79. 79.
    Goldstein J, Smith TR, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 2012 Oct; 52(9): 1402–10PubMedCrossRefGoogle Scholar
  80. 80.
    Landy S, Tepper S, Wein, T, et al. An open-label trial of a sumatriptan auto-injector for migraine [poster]. 54th American Headache Society Annual Scientific Meeting; 2012 Jun 21–24; Los Angeles (CA)Google Scholar
  81. 81.
    Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000; 55: S8–14PubMedGoogle Scholar
  82. 82.
    Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010 Aug 20; 70(12): 1505–18PubMedCrossRefGoogle Scholar
  83. 83.
    Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol Sci 2011 Jun; 32(6): 352–9PubMedCrossRefGoogle Scholar
  84. 84.
    Neeb L, Meents J, Reuter U. 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics 2010 Apr; 7(2): 176–82PubMedCrossRefGoogle Scholar
  85. 85.
    Pregenzer JF, Alberts GL, Im WB, et al. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Br J Pharmacol 1999 May; 127(2): 468–72PubMedCrossRefGoogle Scholar
  86. 86.
    Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001 Oct 13; 358(9289): 1230–4PubMedCrossRefGoogle Scholar
  87. 87.
    Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012 Jun; 13(4): 271–5PubMedCrossRefGoogle Scholar
  88. 88.
    Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002 Jun; 54(2): 233–46PubMedCrossRefGoogle Scholar
  89. 89.
    Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002 Apr 19; 277(16): 14294–8PubMedCrossRefGoogle Scholar
  90. 90.
    Arulmani U, Maassenvandenbrink A, Villalón CM, et al. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004 Oct 1; 500(1–3): 315–30PubMedCrossRefGoogle Scholar
  91. 91.
    Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115–23PubMedCrossRefGoogle Scholar
  92. 92.
    Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31: 712–22PubMedCrossRefGoogle Scholar
  93. 93.
    Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient’s historical triptan response. Headache 2011 Jan; 51(1): 64–72PubMedCrossRefGoogle Scholar
  94. 94.
    Olesen J, Diener H, Husstedt I, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Eng J Med 2004; 350: 1104–10CrossRefGoogle Scholar
  95. 95.
    Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304–12PubMedCrossRefGoogle Scholar
  96. 96.
    Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009 Sep 22; 73(12): 970–7PubMedCrossRefGoogle Scholar
  97. 97.
    Raskin N. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36(7): 995–7PubMedCrossRefGoogle Scholar
  98. 98.
    Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc 2011 Oct; 86(10): 948–55PubMedCrossRefGoogle Scholar
  99. 99.
    Shrewsbury S, Cook R, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) inhaler. Headache 2008; 48: 355–67PubMedCrossRefGoogle Scholar
  100. 100.
    Silberstein SD, McCrory DC. Ergotamine and dihydroer-gotamine: history, pharmacology, and efficacy. Headache 2003 Feb; 43(2): 144–66PubMedCrossRefGoogle Scholar
  101. 101.
    Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons. Headache 2010 Oct; 50(9): 1424–39PubMedCrossRefGoogle Scholar
  102. 102.
    Kori S, Zhang J, Kellerman D, et al. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-ht(1b) and 5-ht(1d) receptors [poster]. 54th American Headache Society Annual Scientific Meeting; 2012 Jun 21–24; Los Angeles (CA)Google Scholar
  103. 103.
    Seybold VS. The role of peptides in central sensitization. Handb Exp Pharmacol 2009; (194): 451–91Google Scholar
  104. 104.
    Dahlöf C, Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan-basic science in relation to migraine treatment. Headache 2012; 52(4): 707–14PubMedCrossRefGoogle Scholar
  105. 105.
    Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth 2010 Dec; 105 Suppl. 1: i69–85PubMedCrossRefGoogle Scholar
  106. 106.
    Collins S, Sigtermans MJ, Dahan A, et al. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 2010 Nov; 11(11): 1726–42PubMedCrossRefGoogle Scholar
  107. 107.
    Kim Y, Cho HY, Ahn YJ, et al. Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models. Pain 2012 May; 153(5): 1022–9PubMedCrossRefGoogle Scholar
  108. 108.
    TorreyPines Therapeutics, Inc. Tezampanel meets primary endpoint in phase IIb clinical trial in acute migraine headache [media release]. 2007 Oct 22 [online]. Available from URL: http://www.drugs.com/clinical_trials/tezampanel-meets-primary-endpoint-phase-iib-clinical-trial-acute-migraine-headache-2332.html
  109. 109.
    Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001 Mar; 41(3): 248–56PubMedCrossRefGoogle Scholar
  110. 110.
    Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan: a human model for development of migraine drugs. Cephalalgia 1996 Oct; 16(6): 412–8PubMedCrossRefGoogle Scholar
  111. 111.
    Olesen J, Jansen-Olesen I. Nitric oxide mechanisms in migraine. Pathol Biol (Paris) 2000 Sep; 48(7): 648–57Google Scholar
  112. 112.
    Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev 1998 Jan; 78(1): 53–97PubMedGoogle Scholar
  113. 113.
    Murphy S. Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 2000 Jan 1; 29(1): 1–13PubMedCrossRefGoogle Scholar
  114. 114.
    Paakkari I, Lindsberg P. Nitric oxide in the central nervous system. Ann Med 1995 Jun; 27(3): 369–77PubMedCrossRefGoogle Scholar
  115. 115.
    Vause CV, Durham PL. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem 2009 Aug; 110(3): 811–21PubMedCrossRefGoogle Scholar
  116. 116.
    Høivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010 Dec; 30(12): 1458–67PubMedCrossRefGoogle Scholar
  117. 117.
    Van der Schueren BJ, Lunnon MW, Laurijssens BE, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol 2009 Mar; 49(3): 281–90PubMedCrossRefGoogle Scholar
  118. 118.
    Sarchielli P, Alberti A, Codini M, et al. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000 Dec; 20(10): 907–18PubMedCrossRefGoogle Scholar
  119. 119.
    Vardi J, Flechter S, Alguati A, et al. PGE2 levels in the saliva of common migraineous women. Headache 1983; 23: 59–61PubMedCrossRefGoogle Scholar
  120. 120.
    Tuca JO, Planas JM, Parellada PP. Increase in PGE2 and TXA2 in the saliva of common migraine patients: action of calcium channel blockers. Headache 1989 Sep; 29(8): 498–501PubMedCrossRefGoogle Scholar
  121. 121.
    Durham PL, Vause CV, Derosier F, et al. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache 2010 May; 50(5): 844–51PubMedCrossRefGoogle Scholar
  122. 122.
    Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994 Jun; 46(2): 205–29PubMedGoogle Scholar
  123. 123.
    Maubach KA, Davis RJ, Clark DE, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 2009 Jan; 156(2): 316–27PubMedCrossRefGoogle Scholar
  124. 124.
    Antonova M, Wienecke T, Maubach K, et al. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain 2011 Oct; 12(5): 551–9PubMedCrossRefGoogle Scholar
  125. 125.
    Rainero I, De Martino P, Pinessi L. Hypocretins and primary headaches: neurobiology and clinical implications. Expert Rev Neurother 2008; 8(3): 409–16PubMedCrossRefGoogle Scholar
  126. 126.
    Peyron C, Tighe DK, Van Den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996–10015PubMedGoogle Scholar
  127. 127.
    Piper DC, Upton N, Smith MI, et al. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000; 12: 726–30PubMedCrossRefGoogle Scholar
  128. 128.
    Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005; 437: 556–9PubMedCrossRefGoogle Scholar
  129. 129.
    Bartsch T, Levy MJ, Knight YE, et al. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004; 109: 367–78PubMedCrossRefGoogle Scholar
  130. 130.
    Merck. A study of the safety and efficacy of MK-6096 for migraine prophylaxis in participants with episodic migraine (MK-6096-020) [ClinicalTrials.gov identifier NCT01513291]. US National Institutes of Health, Clin icalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Oct 15]
  131. 131.
    Sumavel® DosePro®. Product information [online]. Available from URL: http://www.sumaveldosepro.com/[Accessed 2012 Oct 15]
  132. 132.
    Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009 Nov–Dec; 49(10): 1435–44PubMedCrossRefGoogle Scholar
  133. 133.
    Smith TR, Goldstein J, Singer R, et al. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache 2012 Apr; 52(4): 612–24PubMedCrossRefGoogle Scholar
  134. 134.
    Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv 2012 Oct; 25(5): 280–9PubMedCrossRefGoogle Scholar
  135. 135.
    Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache 2009 Nov–Dec; 49(10): 1423–34Google Scholar
  136. 136.
    Rapoport AM. The therapeutic future in headache. Neurol Sci 2012 May; 33 Suppl. 1: 119–25CrossRefGoogle Scholar
  137. 137.
    Silberstein SD, Young WB, Hopkins MM, et al. Dihydro-ergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache 2007; 47(6): 878–85PubMedCrossRefGoogle Scholar
  138. 138.
    Chang D, Kellermann S, Kori S, et al. Acute inhaled safety of MAP0004: studies in healthy volunteers, smokers, and patients with asthma [poster]. 54th Annual Scientific Meeting of the American Headache Society; 2012 Jun 21–24; Los Angeles (CA)Google Scholar
  139. 139.
    Silberstein S, Tepper S, Brandes J, et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004 May 11; 62(9): 1552–7PubMedCrossRefGoogle Scholar
  140. 140.
    Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002 May; 22(4): 309–12PubMedCrossRefGoogle Scholar
  141. 141.
    Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009 Jun; 49(6): 826–37PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Ryan J. Cady
    • 1
  • Candace L. Shade
    • 2
  • Roger K. Cady
    • 2
  1. 1.Center of Biomedical & Life SciencesMissouri State UniversitySpringfieldUSA
  2. 2.Banyan Group, Inc.SpringfieldUSA

Personalised recommendations